Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NY104 PET/CT in Clear Cell Renal Cell Carcinoma
NCT05728515Phase 1Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-NYM005 in clear cell renal cell carcinoma (ccRCC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Biodistribution of 68Ga-NY104 in normal organs at 2 hours and Tumor uptake of 68Ga-NY104 at 2 hours. Started Dec 2021; status: completed.
02
Drugs
68Ga-NYM005
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05728515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728515.